Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
45 /100
MEDIUM RISK
Score updated Aug 28, 2026

URGN — UroGen Pharma Ltd. Dilution Risk Tracker

Track URGN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track URGN — Get alerts when the score changes →

As of August 28, 2026, UroGen Pharma Ltd. (URGN) has a DilutionWatch DilutionScore of 45/100, rated MEDIUM dilution risk. UroGen Pharma Ltd. has a market capitalization of $1.37B, 48.88M shares outstanding, 174 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
65
📊 Float Risk
15
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 7%
💰 Capital Raise model 15%
• Under 12 months cash (9mo)
🔔 Track URGN — Get forecast alerts →

Market Data

Market Cap$1.37B
Shares Outstanding48.88M
Float43.18M
Cash$109.30M
Debt$188.73M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 14.4% shares (2026Q1 vs prior)
174 institutional holders · 53.57M shares
#1 MORGAN STANLEY 7.65M shares
#2 RTW INVESTMENTS, LP 4.54M shares
#3 BlackRock, Inc. 2.85M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.59M
Days to Cover6.6
% of Float10.6%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2025-12-31
xbrl XBRL WARRANT 2024-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual URGN Dilution Snapshot

UroGen Pharma Ltd. (URGN) has a DilutionScore of 45/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track URGN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking URGN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for URGN
URGN FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.